- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Dr Reddy's Receives USFDA VAI Classification for Bachupally Manufacturing Facility

Hyderabad: Dr. Reddy's Laboratories Limited has announced that the United States Food and Drug Administration (USFDA) has classified the outcome of its Good Manufacturing Practices (GMP) inspection at the company's formulations manufacturing facility in Bachupally, Hyderabad, as Voluntary Action Indicated (VAI).
The company further confirmed that the inspection has been officially closed.
In a regulatory update, Dr. Reddy’s Laboratories stated that the inspection was conducted at its Formulations Manufacturing Facility (FTO-3), located in Bachupally, Hyderabad. The company had initially informed the stock exchanges about the GMP inspection through an earlier communication dated August 14, 2026.
Following the inspection, the USFDA classified the outcome as Voluntary Action Indicated (VAI). The regulatory authority also concluded the inspection process, officially closing it under 21 CFR 20.64(d)(3). The company confirmed the development through its regulatory communication to the stock exchanges.
The VAI classification indicates that the inspection outcome has been placed in the Voluntary Action Indicated category. The company did not disclose further details regarding specific inspectional observations or corrective measures in its latest regulatory communication.
Dr. Reddy’s Laboratories is a Hyderabad-headquartered multinational pharmaceutical company with operations across several international markets. Established in 1984, the company has developed a strong presence in the global pharmaceutical industry through its portfolio of generic medicines, active pharmaceutical ingredients (APIs), branded generics, biosimilars and differentiated formulations.
The company operates across multiple therapeutic segments, including gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its business activities encompass the development, manufacturing and marketing of pharmaceutical products for domestic and international markets.
Dr. Reddy’s has a significant presence in regulated markets, including the United States, where pharmaceutical manufacturing facilities and product quality systems are subject to regulatory oversight. Compliance with current Good Manufacturing Practices (cGMP), quality assurance procedures and regulatory requirements remains an important aspect of its manufacturing and global supply operations.
The Bachupally facility forms part of the company’s pharmaceutical manufacturing infrastructure in Hyderabad. Manufacturing facilities supplying regulated international markets are required to maintain quality systems covering manufacturing processes, documentation, equipment, testing and product quality to ensure compliance with applicable regulatory standards.
M. Pharm (Pharmaceutics)
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

